Ian Law, Donatienne Van Weehaeghe, M J Van den Bent, Norbert Galldiks, Nelleke Tolboom, Susan M Chang, Francesco Cicone, Jens Gempt, Eric Guedj, Patrick Y Wen, Julia Furtner, Derek R Johnson, Antoine Verger, Susan C Short, Emilie Le Rhun, Michael A Vogelbaum, Matthias Preusser, Nathalie L Albert, Raymond Y Huang
Journal: European journal of nuclear medicine and molecular imaging 2025;52(5):1822-1839
PMID: 39762634
This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with brain metastases. This practice guideline will define procedure standards for the application of PET imaging in patients with brain metastases in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers.
© 2024. The Author(s).
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.